trading halt

Page 1 of 1
MARKET RELEASE
3 August 2012
HealthLinx Limited
TRADING HALT
The securities of HealthLinx Limited (the “Company”) will be placed in Trading Halt
Session State at the request of the Company, pending the release of an announcement
by the Company. Unless ASX decides otherwise, the securities will remain in Trading
Halt Session State until the earlier of the commencement of normal trading on Tuesday,
7 August 2012 or when the announcement is released to the market.
Security Code: HTX
Kobe Li
Senior Adviser, Listings (Melbourne)
HealthLinx Limited
ABN 88 098 640 352
576 Swan Street Richmond VIC 3121
Telephone: +61 3 9208 4200 I Facsimile: +61 3 9208 4201
www.healthlinx.com.au
3 August 2012
ASX Market Announcements
Australian Securities Exchange Limited
Level 4, Rialto,
525 Collins Street,
Melbourne VIC 3000
REQUEST FOR TRADING HALT
In accordance with Listing Rule 17.2 the Company requests a trading halt pending a material
price sensitive announcement. The reasons are:
• The Company expects to make a material price sensitive announcement within the next 24 hours
regarding a substantial asset sale;
• The Company is concerned about confidentiality because outside parties have been involved in
various ways;
• The Company requests that trading be halted at market open today until immediately after the
expected announcement is made or until 10:00am on Monday August 6, whichever is the earlier;
• The Company is not aware of any reason why its securities should not be temporarily suspended.
Mal Lucas-Smith
Company Secretary
About HealthLinx Limited (ASX:HTX)
HealthLinx uses biomarkers to develop best practice diagnostics that detect and monitor diseases.
First commercial targets are for diseases with high fatality:
• Ovarian cancer diagnostic (OvPlex) targeting US$270m pa market
• Prostate cancer targeting US$350m pa market
A biomarker is a specific biochemical in the body that measures disease or the effects of treatment.
HealthLinx is close to completing the second larger study for OvPlexTM aiming to prove the diagnostic
accuracy for ovarian cancer. This larger study is based on approximately 1150 new samples using
existing OvPlex™ biomarkers. The study will be a robust comparison of sensitivity and specificity
especially for early stage diagnosis in symptomatic women. The objective is to cement the position of
OvPlex™ as the world’s most accurate and efficient ovarian cancer diagnostic. The second study is
partially funded with $750,000 from the Victorian Government Victoria’s Science Agenda Investment